These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36153235)
1. Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer. Hu C; Dong L; Xue W; Pienta KJ PET Clin; 2022 Oct; 17(4):555-564. PubMed ID: 36153235 [TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071 [TBL] [Abstract][Full Text] [Related]
5. How accurate is Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066 [TBL] [Abstract][Full Text] [Related]
6. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Ma TM; Gafita A; Shabsovich D; Juarez J; Grogan TR; Thin P; Armstrong W; Sonni I; Nguyen K; Lok V; Reiter RE; Rettig MB; Steinberg ML; Kupelian PA; Yang DD; Muralidhar V; Chu C; Feng F; Savjani R; Deng J; Parikh NR; Nickols NG; Elashoff D; Czernin J; Calais J; Kishan AU Eur Urol Oncol; 2022 Feb; 5(1):100-103. PubMed ID: 33602654 [TBL] [Abstract][Full Text] [Related]
7. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770 [TBL] [Abstract][Full Text] [Related]
8. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging. Ferraro DA; Burger IA Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295 [TBL] [Abstract][Full Text] [Related]
11. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ( Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951 [TBL] [Abstract][Full Text] [Related]
12. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
13. PET/CT With Giovacchini G; Giovannini E; Riondato M; Ciarmiello A Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673 [TBL] [Abstract][Full Text] [Related]
14. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Roberts MJ; Maurer T; Perera M; Eiber M; Hope TA; Ost P; Siva S; Hofman MS; Murphy DG; Emmett L; Fendler WP Nat Rev Urol; 2023 Jan; 20(1):23-47. PubMed ID: 36473945 [TBL] [Abstract][Full Text] [Related]
15. [Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?]. Berliner C; Kesch C; Fendler WP; Eiber M; Maurer T Urologe A; 2022 Apr; 61(4):384-391. PubMed ID: 35138414 [TBL] [Abstract][Full Text] [Related]
16. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282 [TBL] [Abstract][Full Text] [Related]
17. Risk of metastatic disease on Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284 [TBL] [Abstract][Full Text] [Related]
18. Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer. Connor MJ; Dubash S; Bass EJ; Tam H; Barwick T; Khoo V; Winkler M; Ahmed HU Eur Urol Focus; 2021 Sep; 7(5):951-954. PubMed ID: 33384271 [TBL] [Abstract][Full Text] [Related]